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Abstract: Novel biomarkers might improve the prediction
of mortality in hemodialysis (HD) patients. We simulta-
neously measured the levels of conventional and novel bio-
markers [serum N-terminal pro-brain natriuretic peptide
(NT-proBNP), intact fibroblast growth factor-23 (FGF23),
β2-microglobulin (β2MG), cystatin C, and high-sensitivity
C-reactive protein (hsCRP)] in 307 prevalent Japanese
HD patients. There were 66 all-cause deaths, and 25 car-
diovascular (CV) deaths during 2 years, which were
assessed using Cox models and concordance (C)-statistics.
The addition of NT-proBNP alone (P < 0.05) or
NT-proBNP, hsCRP, and β2MG as a panel (C-statistics:
0.834 vs. 0.776, P < 0.01) to a conventional risk model com-
posed of age, diabetes, and the serum albumin level signif-
icantly improved the prediction of 2-year all-cause
mortality, and the addition of NT-proBNP and hsCRP as
a panel to a conventional risk model composed of age sig-
nificantly improved the prediction of 2-year CV mortality
(P < 0.05) in Japanese prevalent HD patients. Neither
FGF23 nor cystatin C improved mortality prediction.
Key Words: Fibroblast growth factor-23, Hemodialysis
patients, High-sensitivity C-reactive protein, Mortality,
N-terminal pro-brain natriuretic peptide.
Hemodialysis (HD) is associated with significant
excess mortality and high social costs. Thus, the
appropriate identification, risk stratification, and
treatment of HD patients is important.
Conventional risk factors for mortality, such as
advanced age, diabetes, and low serum albumin
levels, frequently coexist in HD patients, but they
cannot fully account for the high prevalence of
mortality in these patients. Therefore, research must
be performed to create better and easier-to-use tools
for mortality risk stratification in this population.
Although numerous previous studies have explored
various novel biomarkers for predicting mortality in
HD patients, but the majorities of these studies were
conducted in the United States (US) or Europe.
The 5-year survival rates of dialysis patients in the
2009 cohort was 41.5% in the US (1) and 60.5% in
Japan (2), while that for the 2005–2009 cohort in
Europe was 63.3% (3). Mean age and the association
of comorbid conditions such as cardiovascular
diseases and diabetes differed across regions, and
certain features of dialysis treatments, such as a
single treatment time and the amount of blood flow,
are unique to Japan (4). Based on these findings,
the best biomarkers for predicting mortality in
Japanese HD patients might differ from those for
American and European HD patients.
Specific biomarkers were selected for this study
on the basis of the commercial availability of assays
and published data regarding the prognostic value
of potential biomarkers of mortality in HD
patients. N-terminal pro-brain natriuretic peptide
(NT-proBNP) can be used to non-invasively mea-
sure cardiac stretching, and there have been many
reports about the associations between elevated
serum NT-proBNP levels and all-cause or cardio-
vascular (CV) mortality in HD patients (5–8).
High-sensitivity C-reactive protein (hsCRP) is a
key marker of inflammation, and inflammation is
a major risk factor for mortality in patients with
chronic kidney disease (6,8). Fibroblast growth fac-
tor 23 (FGF23) is secreted by osteocytes, and
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promotes phosphaturia and decreases calcitriol pro-
duction (9). There is a pervasive view that elevated se-
rum FGF23 levels are associated with increased
mortality in HD patients (9,10). Cystatin C is a well
known alternative marker of kidney function, and
strong correlations have been detected between the
serum levels of cystatin C and residual renal function
in dialysis patients (11). Furthermore, residual renal
clearance was found to be a predictor of survival in
dialysis patients (12). β2-microglobulin (β2MG) is a
low-molecular-weight protein (11800 Da) and is
considered to be a surrogate marker of middle
molecular-weight uremic toxins, which might affect
nutritional status and have immunosuppressive ef-
fects, and β2MG is reported to be a significant pre-
dictor of mortality in maintenance HD patients
(13). Thus, we undertook this analysis to assess
whether the addition of five biomarkers
(NT-proBNP, hsCRP, FGF23, cystatin C, and
β2MG) could improve the prediction of 2-year
all-cause and/or CV mortality in Japanese prevalent
HD patients.
PATIENTS AND METHODS
The subjects of this study were 307 prevalent HD
patients who were treated at Ichiyokai Harada Hos-
pital, Japan. Patients with hepatic insufficiency, acute
or chronic infections, severe heart failure, or malig-
nancies were excluded. This study was approved by
the institutional review board of Ichiyokai Harada
Hospital, Hiroshima, Japan (authorization No.
201201), and conforms to the provisions of the Decla-
ration of Helsinki (as revised in Tokyo in 2004). All
of the patients underwent routine HD three times a
week (4 h per session) using standard high-flux
dialysis membranes. Underlying diseases included
chronic glomerulonephritis (125 patients, 40.7%),
diabetic nephropathy (112 patients, 36.5%),
nephrosclerosis (38 patients, 12.4%), polycystic
kidney disease (11 patients, 3.6%), other diseases
(11 patients, 3.6%), and unknown conditions
(10 patients, 3.3%). The patients’ (N = 307) serum
NT-proBNP, hsCRP, intact FGF23, cystatin C,
β2MG, Kt/Vurea, hemoglobin (Hb), serum albumin,
phosphate, intact parathyroid hormone (iPTH), and
albumin-adjusted serum calcium (Ca) levels were
measured only at baseline just before and at the
end (for Kt/Vurea only) of the first day of the first
week dialysis session in September 2012. In addition,
the 24-h urine volume at 1 day before the baseline
blood sampling was measured from the patients that
produced ≥100 mL/day of urine. The urinary volume
was considered to be zero in patients that produced
<100 mL/day of urine. These values have been used
for statistics. In each case, we examined the subject’s
age, sex, dialysis vintage, pre-HD systolic blood
pressure (BP), pre-HD diastolic BP. urinary volume
(mL/day), and whether they were suffering from
diabetes mellitus. CV death, including death due to
myocardial infarction, congestive heart failure,
peripheral arterial disease, and/or stroke, was diag-
nosed based on the patients’ medical records. The
patients’ NT-proBNP and hsCRP levels were
determined using immunoassays (ECLIA Roche
Diagnostics, GMBH Mannheim, Germany) by
BML Inc. (Tokyo, Japan). The patients’ serum
intact FGF23 levels were determined by SRL Inc.
(Tokyo, Japan) using a sandwich ELISA kit
(Kainos Laboratories, Tokyo, Japan). Other clinical
biochemical analyses were performed at our hospi-
tal’s laboratory.
Statistical analysis
All statistical analyses were performed with SPSS
software (version 22.0, IBM, Armonk, NY, USA).
The parameters that demonstrated normal distribu-
tions are expressed as mean ± standard deviation
values and were analyzed with the t-test. Non-
parametric variables are expressed as median values
and interquartile ranges (IQR) and were analyzed
with the Wilcoxon-signed rank test.
The additional predictive value of the novel bio-
markers was evaluated using the following steps for
each of the outcomes, i.e., 2-year all-cause mortality
or CV mortality.
Base model: We first developed univariate and
multivariate Cox proportional hazards models for
2-year all-cause or CV mortality in prevalent HD
patients using conventional risk markers. Indepen-
dent variables included age, sex, dialysis vintage,
presence of diabetes, urine volume, Kt/Vurea, serum
albumin and serum phosphate. Base model was
composed of only significant traditional independent
variables.
Novel models: Then we added individual novel
biomarkers (NT-proBNP, hsCRP, FGF23, cystatin C
and β2MG) to the base model and calculated
adjusted hazard ratios (HR) for each model using
multivariate Cox proportional hazards models.
NT-proBNP, hsCRP, FGF23 and cystatin C that
exhibited non-parametric distributions were trans-
formed to the logarithm (log) to achieve normality
prior to the analyses.
The optimal model for 2-year all-cause or CV mor-
tality: We created an optimal model for 2-year all
cause or 2-year CV mortality by adding all of the
novel biomarkers that had significant positive effects
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on the prediction of the target variable to the base
model. Multivariate logistic regression analyses for
2-year all-cause and CV mortality were also per-
formed on all models. Akaike Information Criterion
(AIC) (14) for the overall fit of the models and
C-statistics (area under the ROC curves) (6,15) for
model discrimination were obtained. Statistical tests
for differences in C-statistics were also performed
(15). The cut-off points of each model for the
non-survivor and survivor groups were obtained in
the optimal model. Kaplan–Meier survival analyses
for predicting 2-year all-cause mortality using the
cut-off points for the non-survivor group in the
optimal model were also performed.
RESULTS
All of the subjects (N = 307) were Japanese, and
baseline clinical data are shown in Table 1. After
24 months, a total of 66 patients had died, and the
causes of death included CV mortality, infection, ma-
lignancy, sudden death, wasting, other diseases and
unknown in 25 (37.9%), 14 (21.2%), seven (10.6%),
seven (10.6%), two (3.0%), nine (13.7%), and two
(3.0%) patients, respectively. The median ages of
non-survivors were significantly higher than survi-
vors (P < 0.001). The non-survivors exhibited a
higher frequency of diabetes (47.0% vs. 33.6%,
P < 0.05); had lower pre-HD diastolic BP levels
(P < 0.01), and displayed lower serum albumin
(33.3 ± 4.5 g/L vs. 36.2 ± 3.6 g/L, P < 0.001), phos-
phate (P < 0.05), iPTH (P < 0.05), FGF23
(P < 0.05), and cystatin C levels (P < 0.05) than
the survivors. On the other hand, the NT-proBNP
[10312 (5274–28953) pg/mL vs. 3343 (1451–8719)
pg/mL, P < 0.001] and serum hsCRP [1.35
(0.59–6.93) mg/L vs. 0. 95 (0. 28–2.74) mg/L,
P < 0.01] levels of the non-survivors were signifi-
cantly higher than those of the survivors. No
significant difference in serum β2MG values were
detected between the groups.
Cox proportional hazards regression analyses of
2-year all-cause and CV mortality in prevalent HD
patients based on conventional markers are shown in
Table 2. In the univariate analyses, age (P < 0.0001),
urinary volume (P < 0.05), the serum albumin level
(P < 0.0001), and the serum phosphate level
(P < 0.01) were found to be significantly associated
with 2-year all-cause mortality, and sex (P = 0.06)
and presence of diabetes (P = 0.07) were shown to
be marginally associated with 2-year all-cause mor-
tality (Table 2A). In the multivariate analysis, only
age (P < 0.0001), presence of diabetes (P < 0.05),
and the serum albumin level (P < 0.05) were found
to be significantly associated with 2-year all-cause
mortality (Table 2A). While, age (P < 0.0001) and
the serum albumin level (P < 0.01), and age
(P < 0.0001) alone were found to be significantly as-
sociated with 2-year CV mortality in the univariate
and multivariate analyses, respectively (Table 2B).
TABLE 1. Subjects’ baseline clinical data
All Survivors Non-survivors
N 307 241 66
Age (years) 68 ± 13 66 ± 12 76 ± 11***
Sex (male) (%) 188/307 (61.0) 154/241 (63.9) 34/66 (51.5)*
Dialysis vintage (months) 71 (32–146) 70 (34–152) 77 (25–140)
Presence of diabetes (%) 112/307 (36.5) 81/160 (33.6) 31/66 (47.0)*
Pre-HD systolic BP (mmHg) 151 (134–165) 152 (136–165) 142 (130–166)
Pre-HD diastolic BP (mmHg) 79 (70–89) 80 (72–91) 74 (64–82)***
Urinary volume of <100 mL/day (%) 239/307 (77.9) 183/241 (75.9) 56/66 (84.8)
KT/V urea (/dialysis session) 1.42 (1.28–1.54) 1.41 (1.28–1.53) 1.42 (1.27–1.58)
Hb (g/L) 114(105–122) 114 (106–123) 110 (102–118)
Serum albumin (g/L) 35.7 ± 4.0 36.2 ± 3.6 33.3 ± 4.5***
Albumin-adjusted serum Ca (mmol/L) 2.35 (2.25–2.48) 2.35 (2.25–2.48) 2.40 (2.28–2.58)
Serum phosphate (mmol/L) 1.62 ± 0.45 1.65 ± 0.42 1.49 ± 0.55*
Serum iPTH (pg/mL) 95 (41–182) 102 (46–189) 71 (22–150)*
NT-proBNP (pg/mL) 4423 (1823–11728) 3343 (1451–8719) 10312 (5274–28953)***
Serum hsCRP (mg/L) 0.99 (0.35–3.15) 0. 95 (0. 28–2.74) 1.35 (0.59–6.93)**
FGF23 (pg/mL) 1560 (331–5730) 1720 (473–6105) 580 (155–4653)*
Serum cystatin C (ng/mL) 6.6 (5.9–7.2) 6.7 (6.0–7.3) 6.1 (5.7–6.9)*
Serum β2MG (mg/L) 26.9 ± 6.4 26.5 ± 6.4 28.4 ± 6.1
Data are shown as mean ± standard deviation or median (interquartile ranges), as appropriate. *P<0.05, **P < 0.01, ***P < 0.001
compared with the survivors; β2MG, β2-microglobulin; BP, blood pressure; Ca, calcium; FGF23, fibroblast growth factor-23; HD,
hemodialysis; hsCRP, high-sensitivity C-reactive protein; iPTH, intact parathyroid hormone; NT-proBNP, N-terminal pro-brain natriuretic
peptide.
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Thus, in the base models we included age, presence
of diabetes, and the serum albumin level as
independent predictors of 2-year all-cause mortality
and age as an independent predictor of 2-year CV
mortality.
Predictive models of 2-year all-cause mortality in
prevalent HD patients based on the conventional
and novel biomarkers were assessed by Multivariate
Cox proportional hazards regression analyses
(Table 3). Model 1 was the base model and only in-
cluded the conventional markers that were found to
be significantly associated with 2-year all-cause mor-
tality, i.e., age (P < 0.0001), presence of diabetes
(P < 0.05), and the serum albumin level (P < 0.01).
After the serum Log NT-proBNP was added to the
base model, Log NT-proBNP (P < 0.0001), age
(P < 0.0001), and serum albumin level (P < 0.05),
but not the presence of diabetes were found to be sig-
nificantly associated with 2-year all-cause mortality
(Table 3, Model 2). After the addition of Log hsCRP
to the base model, Log hsCRP (P < 0.01), age
(P < 0.0001), and presence of diabetes (P < 0.05)
but not the serum albumin level, were found to be
significantly associated with 2-year all-cause mortal-
ity (Table 3, Model 3). Neither adding Log FGF23
nor Log cystatin C to the base model resulted in
any improvement in mortality risk stratification
(Table 3, Models 4 and 5). After the serum β2MG
level was added to the base model, the serum
β2MG level (P < 0.01), age (P < 0.0001), presence
of diabetes (P < 0.05), and the serum albumin level
(P < 0.05) were all found to be significantly associ-
ated with 2-year all-cause mortality (Table 3, Model
6). Model 7 is the optimal model and included con-
ventional markers in the base model and all novel
biomarkers that exhibited significance in Models
2–6. In Model 7, age (HR: 1.08, P < 0.0001),
presence of diabetes (HR: 1.78, P < 0.05), Log
NT-proBNP (HR: 2.17, P < 0. 001), Log hsCRP
(HR: 1.73, P < 0.05), and β2MG (HR: 1.04,
P< 0.05) were all found to be significantly associated
with 2-year all-cause mortality, but the serum albu-
min level was not (HR: 0.77, P = 0.43). Figure 1
shows the receiver operating characteristic (ROC)
curves for the prognostic performance of predicting
2-year all-cause mortality from models 1–7 in
Table 3. During the addition of individual novel bio-
markers to the base model, Model 2 (the addition of
Log NT-proBNP) had large impact on the model’s fit
(AIC: 254.8 vs. 272.6) and discriminatory ability, the
latter of which improved by 4.4% compared with
the base model (C-statistics: 0.820 vs 0.776,
P < 0.05) (Model 2). The C-statistics were not signif-
icantly improved in Models 3, 4, 5 and 6. TheTA
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decrease in AIC (247.2 vs. 272.6) and a 5.7 % in-
crease in C-statistics (0.833 vs. 0.776, P < 0.01) for
2 year all-cause mortality were observed in Model 7
(the optimal model). The 2-year cut-off values in
the non-survivor group vs. survivor group were as
follows; age; 68 vs. 70 years old, serum albumin; 36
vs. 36 g/L, NT-proBNP; 8742 vs. 2947 ng/mL,
high-sensitivity CRP 3.79 vs. 10.40 mg/L, β2-MG;
31.9 vs. 27.5 mg/L, which resulted in sensitivity and
specificity values of 94.4% and 69.1% in both groups
(data for the non-survivor group are shown in
Figure 2, while data for the survivor group are not
shown).
Kaplan–Meier 2-year survival curves for prevalent
HD patients based on the baseline cut-off values of
non-survivors group for each of the parameters in-
cluded in the optimal model (Table 3, Model 7) are
shown in Figure 2.
Predictive models of 2-year CV mortality in preva-
lent HD patients based on conventional and novel
biomarkers were assessed by Multivariate Cox pro-
portional hazards regression analyses (Table 4).
During the addition of individual novel biomarkers
to the base model, Log NT-proBNP (P < 0.0001)
and age (P < 0.0001) showed significant association
with 2-year CV mortality (Model 2). After the addi-
tion of Log hsCRP to the base model, Log hsCRP
(P< 0.01) and age (P< 0.0001) were found to be sig-
nificantly associated with 2-year CVmortality (Model
3). Conversely, Log FGF23, Log cystatin C, and the
β2MG level (Models 4–6) were not shown to be signif-
icantly associated with 2-year CVmortality after their
addition to the base model. Model 7 is the optimal
model, and included conventional marker in the base
model and all of novel biomarkers that exhibited sig-
nificance in Models 2–6. In Model 7, age (HR: 1.09,
P < 0.0001) and the serum Log NT-proBNP level
(HR: 4.79, P < 0.0001) were demonstrated to be
significantly associated with 2-year CV mortality, al-
though the association between the serumLog hsCRP
level and 2-year CV mortality was not significant
(HR: 1.81, P = 0.09). Figure 3 shows the ROC curves
for the prognostic performance of predicting 2-year
CV mortality from models 1–7 in Table 4. Compared
with the base model (Model 1), the C-statistics were
not significantly improved in Models 2, 3, 4, 5 and 6.
Compared with the base model, the decrease in AIC
(138.2 vs. 162.2) and 10.5 % increase in C-statistics
(0.862 vs. 0.757, P < 0.05) were observed in Model 7,
and the optimal cut-off values in the 2 year-CV death
and survivor groups were the same and for age,
NT-proBNP, and hsCRP were 81 years, 5335 ng/mL,
and 0.75 mg/L, respectively. These cut-off points
resulted in sensitivity 88.0 vs. 75.5% and specificity
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FIG. 1. The receiver operating characteristic curves showing the prognostic performance of predicting 2-year all-cause mortality for models
1–7 (in Table 3). Note that C-statistics of the model 2 (P< 0.05) and the model 7 (P< 0.01) are significantly higher than that derived from the
base model (model 1). AIC, Akaike information criterion; DM, presence of diabetes mellitus; P, probability compared with C-statistics for
model 1. [Color figure can be viewed at wileyonlinelibrary.com]
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N N
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P
FIG. 2. Kaplan–Meier 2-year survival curves of prevalent HD patients. The groups were divided based on the cut-off values of each marker
for non-survivors group in the best model (model 7 in Table 3). [Color figure can be viewed at wileyonlinelibrary.com]
6 K Yamashita et al.
© 2017 The Authors. Therapeutic Apheresis and Dialysis published by John Wiley & Sons Australia, Ltd on behalf of International Society for Apheresis,
Japanese Society for Apheresis, and Japanese Society for Dialysis TherapyTher Apher Dial, Vol. ••, No. ••, 2017
values of 75.5 vs. 88.0.%, respectively in 2 year-CV
death vs. survivor groups (data not shown).
DISCUSSION
It is reported that good diagnostic tests are charac-
terized by C-statistics values of >0.8 (16). In our
study, a model consisting of age, diabetes, and the se-
rum levels of albumin and NT-pro BNP (the signifi-
cant model for 2-year all-cause mortality), a model
consisting of age, diabetes, and the serum levels of al-
bumin, NT-proBNP, hsCRP, and β2MG (the optimal
model for predicting 2-year all-cause mortality), and
a model consisting of age and the serum levels of
NT-proBNP and hsCRP (the optimal model for
predicting 2-year CV mortality) exhibited C-statistics
values of 0.820, 0.833, and 0.862, respectively,
whereas the base models for 2-year all-cause mortal-
ity and CV mortality did not reach the 0.8 C-statistics
threshold.
The cut off point for serum albumin levels in both
groups (survivors and non-survivors) was 36.0 g/L in
HD patients in the present study, and the multivari-
ate adjusted population-attributable fraction of death
due to baseline serum albumin < 3.8 g/dL was 19%
in a 2-year cohort of 58058 maintenance HD patients
(17). The relationship observed between low serum
albumin levels and mortality in HD patients may be
due to cachexia, which is known to be responsible
for the worse survival of these patients (18).
Previously, there have been many reports about
the associations between elevated serum NT-
proBNP levels and all-cause or CV mortality in HD
patients (5–8). The elevated serum NT-proBNP
levels have dual significance as a marker of LVH
and fluid volume overload, both of which are known
to have a great impact on all-cause and CV mortality
in HD patients (5,19). We measured all biomarkers
at baseline only, just before the beginning of the first
week’s HD session and considered the pre-HD levels
of NT-proBNP to be higher than post-HD
levels reflecting high values; however, the pre-HD
levels of NT-proBNP were also predictive of mortal-
ity, as previously reported (5). A previous study
showed that an extracellular water (ECW) excess be-
fore dialysis was strongly associated with mortality,
and these patients also had increased ECWafter dial-
ysis (19). From a clinical perspective, it is important
to keep in mind that our NT-proBNP cut-off values
(8742 pg/mL for 2-year all-cause mortality and
5335 pg/mL for 2-year CV mortality) have high sensi-
tivity (94.4%, 88.0%, respectively) and acceptable
specificity (69.1%, 88.0%, respectively). The NT-
proBNP cut-off value for 2-year all-cause mortality
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identified in this study were comparable with the
value used in the previous studies (5,7,20).
The results of previous studies regarding the im-
pact of serum hsCRP concentrations on mortality in
end-stage renal disease patients were not consistent.
It is reported that hsCRP is a significant predictor
of all-cause mortality in incident HD patients (6)
and prevalent HD patients (8). While, Oh et al. (7)
and Madsen et al. (5) reported that hsCRP was not
a significant predictor of all-cause mortality in inci-
dent HD patients and prevalent HD patients, respec-
tively. The current study found that hsCRP is
associated with the risk of 2-year all-cause and CV
mortality in prevalent HD patients, although NT-
proBNP, demonstrated to be the most powerful
biomarker.
In the present study, the optimal model for
predicting 2-year all-cause mortality including serum
β2MG levels is consistent with previous findings (13).
β2MG may be directly, rather than indirectly, for ex-
ample, as a surrogate of RRF, implicated in the
greater morbidity and mortality associated with end
stage kidney disease (21).
FGF23 has been included in the statistical analysis
and did not have a significant impact on mortality in
this study, which is in contrast to previous findings
(9,10). Olauson et al. (22) reported that no associa-
tion exists between high serum FGF23 levels and
mortality in HD patients, which is consistent with
our findings. Furthermore, non-diabetes mellitus
patients were found to have higher plasma FGF23
levels than diabetes mellitus patients (23). The dis-
crepancies between the results of these studies might
be partly explained by differences in gender, previ-
ous CV diseases, residual renal function levels (22),
variations in the prevalence of diabetes (23), and ra-
cial differences (9).
Cystatin C was less influenced by factors other
than glomerular filtration rate (24), and is consid-
ered to be a significant predictor of all-cause
mortality and CV events in non-dialysis chronic
kidney disease patients (6) and incident dialysis
patients (24). In our study, 77.9% of the subjects
exhibited urinary volumes of <100 mL/day, and
the addition of cystatin C to the base model did
not improve the model’s ability to predict 2-year
all-cause or CV mortality in prevalent HD patients
with depleted renal function.
This study had several limitations. First, since the
subjects were all Japanese prevalent HD patients,
the associations detected between various bio-
markers and mortality might not be applicable to
other populations. Second, the sample size and num-
ber of adverse events were relatively small, and
therefore, the Cox regression analysis was restricted
to a limited number of potential confounders. Third,
the biomarker measurements were only performed
once. Therefore, it was difficult to examine whether
the changes in the levels of the biomarkers had any
impact on clinical outcomes.
FIG. 3. The receiver operating characteris-
tic curves showing the prognostic perfor-
mance of predicting 2-year cardiovascular
mortality for models 1–7 (in Table 4). Note
that only C-statistic of the model 7
(P< 0.05) is significantly higher than that de-
rived from the base model (model 1). AIC,
Akaike information criterion; P, probability
compared with C-statistics for model 1.
[Color figure can be viewed at
wileyonlinelibrary.com]
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CONCLUSIONS
The addition of novel biomarkers, i.e., N-terminal
pro-brain natriuretic peptide alone or NT-proBNP,
high-sensitivity C-reactive protein, and β2MG as a
panel, to a conventional risk model (age, presence
of diabetes, serum albumin) significantly improved
the prediction of 2-year all-cause mortality, and the
addition of novel biomarkers, i.e., N-terminal
pro-brain natriuretic peptide and high-sensitivity
C-reactive protein as a panel, to a conventional risk
model (age) significantly improved the prediction of
2-year cardiovascular mortality in Japanese
prevalent hemodialysis patients.
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